US Foot and Ankle Allograft Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

October 2017 | 150 pages | ID: UC989FA6D14EN
Data Bridge Market Research

Abstracts

In this region, U.S. foot and ankle allograft market is projected to reach USD 138.04 million by 2024 from USD 95.05 million in 2016, at a CAGR of 4.8% in the forecast period 2017 to 2024

Integra LifeSciences Corporation is going to dominate the U.S. foot and ankle allograft market following with CONMED Corporation and Wright Medical Group N.V., along with others such as Stryker,

• Zimmer Biomet
• Lattice Biologics Ltd.
• Bone Bank allografts
• RTI surgical, Inc.
• Arthrex Inc.
• JRF Ortho and AlloSource.

The U.S. foot and ankle allograft market is segmented on the basis of surgery type and end user. The U.S. foot and ankle allograft market is segmented into 6 types: allograft wedges, allograft tendons, allograft acellular dermal matrix, cartilage allograft matrix, skin allografts, and amniotic membranes.

On the basis of end users, the market is classified into orthopedic clinics, hospitals and ambulatory surgical centres.

Contents

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF U.S. FOOT AND ANKLE ALLOGRAFT MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. YEARS CONSIDERED FOR THE STUDY
2.3. CURRENCY AND PRICING
2.4. RESEARCH METHODOLOGY
2.5. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6. SECONDARY SOURCES
2.7. ASSUMPTIONS

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

5. MARKET OVERVIEW

5.1. DRIVERS
  5.1.1. INCREASING NUMBERS OF SPORTS INJURIES
  5.1.2. INCREASED NUMBER OF ARTHROSCOPIC SURGERIES
  5.1.3. RISING NUMBER OF AGING AND GERIATRIC POPULATION
  5.1.4. INCREASING INCIDENCE OF CHRONIC WOUNDS AND DIABETIC FOOT ULCER
  5.1.5. TECHNOLOGICAL ADVANCEMENT & NEW PRODUCT LAUNCES
5.2. RETRAINS
  5.2.1. LACK OF AWARENESS
5.3. OPPORTUNITIES
  5.3.1. EMERGING MARKET AND MEDICAL TOURISM
5.4. CHALLENGE
  5.4.1. LACK OF TRAINED STAFF

6. U.S. FOOT AND ANKLE ALLOGRAFT MARKET, BY SURGERY TYPE

6.1. INTRODUCTION
6.2. ORTHOPEDIC RECONSTRUCTION
  6.2.1. NON-UNIONS FRACTURES
  6.2.2. ARTHRODESIS PROCEDURES (FUSION)
  6.2.3. OSTEOTOMY PROCEDURES
6.3. CARTILAGE RESTORATION
  6.3.1. TALAR DOME REPAIR
  6.3.2. TIBIAL PLAFOND REPAIR
  6.3.3. METATARSAL REPAIR
  6.3.4. TALONAVICULAR JOINT REPAIR
  6.3.5. SUBTALAR JOINT REPAIR
6.4. SOFT TISSUE TENDON & LIGAMENT REPAIR
  6.4.1. TENDON AUGMENTATION
  6.4.2. LIGAMENT REPAIR
  6.4.3. FAT PAD REPLACEMENT
  6.4.4. PLANTAR PLATE REPAIR
6.5. WOUND CARE
  6.5.1. ANKLE ULCER TREATMENT
  6.5.2. NEUROPATHIC FOOT ULCER TREATMENT

7. U.S. FOOT AND ANKLE ALLOGRAFT MARKET, BY PRODUCT TYPE

7.1. OVERVIEW
7.2. ALLOGRAFT WEDGES
7.3. ALLOGRAFT TENDONS
7.4. ALLOGRAFT ACELLULAR DERMAL MATRIX
7.5. CARTILAGE ALLOGRAFT MATRIX
7.6. SKIN ALLOGRAFTS
7.7. AMNIOTIC MEMBRANES

8. U.S. FOOT AND ANKLE ALLOGRAFT MARKET, BY END USER

8.1. OVERVIEW
8.2. U.S. FOOT AND ANKLE ALLOGRAFT MARKET: ORTHOPEDIC CLINICS
8.3. U.S FOOT AND ANKLE ALLOGRAFT MARKET: HOSPITALS
8.4. U.S. FOOT AND ANKLE ALLOGRAFT MARKET: AMBULATORY SURGICAL CENTRE

9. U.S. FOOT AND ANKLE ALLOGRAFT MARKET, COMPANY LANDSCAPE

9.1. COMPANY SHARE ANALYSIS FOR FOOT AND ANKLE RECONSTRUCTION ALLOGRAFT MARKET: U.S.
9.2. COMPANY SHARE ANALYSIS FOR FOOT AND ANKLE WOUND CARE ALLOGRAFT MARKET: U.S.

10. COMPANY PROFILE

10.1. STRYKER
  10.1.1. COMPANY OVERVIEW
  10.1.2. REVENUE ANALYSIS
  10.1.3. PRODUCT PORTFOLIO
  10.1.4. RECENT DEVELOPMENTS
10.2. CONMED CORPORATION
  10.2.1. COMPANY OVERVIEW
  10.2.2. REVENUE ANALYSIS
  10.2.3. PRODUCT PORTFOLIO
  10.2.4. RECENT DEVELOPMENTS
10.3. WRIGHT MEDICAL GROUP N.V.
  10.3.1. COMPANY OVERVIEW
  10.3.2. REVENUE ANALYSIS
  10.3.3. PRODUCT PORTFOLIO
  10.3.4. RECENT DEVELOPMENTS
10.4. ALLOSOURCE
  10.4.1. COMPANY OVERVIEW
  10.4.2. REVENUE ANALYSIS
  10.4.3. PRODUCT PORTFOLIO
  10.4.4. RECENT DEVELOPMENTS
10.5. AMNIOX MEDICAL, INC.
  10.5.1. COMPANY OVERVIEW
  10.5.2. REVENUE ANALYSIS
  10.5.3. PRODUCT PORTFOLIO
  10.5.4. RECENT DEVELOPMENTS
10.6. BONE BANK ALLOGRAFTS
  10.6.1. COMPANY OVERVIEW
  10.6.2. REVENUE ANALYSIS
  10.6.3. PRODUCT PORTFOLIO
  10.6.4. RECENT DEVELOPMENTS
10.7. RTI SURGICAL, INC
  10.7.1. COMPANY OVERVIEW
  10.7.2. REVENUE ANALYSIS
  10.7.3. PRODUCT PORTFOLIO
  10.7.4. RECENT DEVELOPMENTS
10.8. ZIMMER BIOMET
  10.8.1. COMPANY OVERVIEW
  10.8.2. REVENUE ANALYSIS
  10.8.3. PRODUCT PORTFOLIO
  10.8.4. RECENT DEVELOPMENTS
10.9. ARTHREX, INC
  10.9.1. COMPANY OVERVIEW
  10.9.2. REVENUE ANALYSIS
  10.9.3. PRODUCT PORTFOLIO
  10.9.4. RECENT DEVELOPMENTS
10.10. JRF ORTHO
  10.10.1. COMPANY OVERVIEW
  10.10.2. REVENUE ANALYSIS
  10.10.3. PRODUCT PORTFOLIO
  10.10.4. RECENT DEVELOPMENTS
10.11. MUSCULOSKELETAL TRANSPLANT FOUNDATION (MTF)
  10.11.1. COMPANY OVERVIEW
  10.11.2. REVENUE ANALYSIS
  10.11.3. PRODUCT PORTFOLIO
10.12. INTEGRA LIFESCIENCES CORPORATION
  10.12.1. COMPANY OVERVIEW
  10.12.2. REVENUE ANALYSIS
  10.12.3. PRODUCT PORTFOLIO
  10.12.4. RECENT DEVELOPMENTS
10.13. LATTICE BIOLOGICS LTD.
  10.13.1. COMPANY OVERVIEW
  10.13.2. REVENUE ANALYSIS
  10.13.3. PRODUCT PORTFOLIO
  10.13.4. RECENT DEVELOPMENTS

11. RELATED REPORTS

List Of Tables

LIST OF TABLES

TABLE 1 SURGERY NUMBERS OF NON UNIONS FRACTURES, 2010 -2020 31
TABLE 2 SURGERY NUMBERS OF ARTHRODESIS PROCEDURES (FUSION), 2010 -2020 32
TABLE 3 SURGERY NUMBERS OF OSTEOTOMY PROCEDURES, 2010 -2020 32
TABLE 4 SURGERY NUMBERS OF TALAR DOME REPAIR, 2010 -2020 33
TABLE 5 SURGERY NUMBERS OF TIBIAL PLAFOND REPAIR, 2010 -2020 33
TABLE 6 SURGERY NUMBERS OF METATARSAL REPAIR, 2010 -2020 34
TABLE 7 SURGERY NUMBERS OF SUBTALAR JOINT REPAIR, 2010 -2020 34
TABLE 8 SURGERY NUMBERS OF LIGAMENT REPAIR, 2010 -2020 35
TABLE 9 SURGERY NUMBERS OF FAT PAD REPLACEMENT, 2010 -2020 35
TABLE 10 SURGERY NUMBERS OF ANKLE ULCER TREATMENT, 2010 -2020 36
TABLE 11 SURGERY NUMBERS OF NEUROPATHIC FOOT ULCER TREATMENT, 2010 -2020 36
TABLE 12 U.S. FOOT AND ANKLE ALLOGRAFT MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION) 39
TABLE 13 U.S. ALLOGRAFT WEDGES MARKET, BY SURGERY TYPE, 2015– 2024 (USD MILLION) 40
TABLE 14 U.S. ALLOGRAFT TENDON MARKET, BY SURGERYTYPE, 2015– 2024 (USD MILLION) 42
TABLE 15 U.S. ALLOGRAFT ACELLULAR DERMAL MATRIX MARKET, BY SURGERY TYPE, 2015– 2024 (USD MILLION) 43
TABLE 16 U.S. CARTILAGE ALLOGRAFT MATRIX MARKET, BY SURGERY TYPE, 2015– 2024 (USD MILLION) 44
TABLE 17 U.S. SKIN ALLOGRAFTS MARKET, BY SURGERY TYPE, 2015– 2024 (USD MILLION) 45
TABLE 18 U.S. AMNIOTIC MEMBRANES MARKET, BY SURGERY TYPE, 2015– 2024 (USD MILLION) 46
TABLE 19 U.S. FOOT AND ANKLE ALLOGRAFT MARKET, BY END USER, 2015– 2024 (USD MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 U.S. FOOT AND ANKLE ALLOGRAFT MARKET: SEGMENTATION 15
FIGURE 2 U.S. FOOT AND ANKLE ALLOGRAFT MARKET: DATA TRIANGULATION 17
FIGURE 3 U.S. FOOT AND ANKLE ALLOGRAFT MARKET RESEARCH SNAPSHOT 18
FIGURE 4 U.S. FOOT AND ANKLE ALLOGRAFT MARKET BOTTOM UP APPROACH 19
FIGURE 5 U.S. FOOT AND ANKLE ALLOGRAFT MARKET TOP DOWN APPROACH 19
FIGURE 6 U.S. FOOT AND ANKLE ALLOGRAFT MARKET: INTERVIEW DEMOGRAPHICS 20
FIGURE 7 INCREASED NUMBER OF ORTHOPEDIC SURGERIES AND SPORTS INJURIES ARE EXPECTED TO DRIVE THE MARKET FOR U.S. FOOT AND ANKLE ALLOGRAFT IN THE FORECAST PERIOD 2017 TO 2024 23
FIGURE 8 ALLOGRAFT ACELLULAR DERMAL MATRIX MARKET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. FOOT AND ANKLE ALLOGRAFT MARKET IN 2017 & 2024 24
FIGURE 9 U.S. FOOT AND ANKLE ALLOGRAFT MARKET: BY PRODUCT TYPE, SNAPSHOT 2016 38
FIGURE 10 U.S. FOOT AND ANKLE ALLOGRAFT MARKET DOMINATED BY ORTHOPEDIC CLINICS SEGMENT 48
FIGURE 11 U.S. FOOT AND ANKLE ALLOGRAFT MARKET: BY END-USER, SNAPSHOT 2016 49
FIGURE 12 U.S. FOOT AND ANKLE RECONSTRUCTION ALLOGRAFT MARKET: COMPANY SHARE 2016 (%) 53
FIGURE 13 U.S. FOOT AND ANKLE WOUND CARE ALLOGRAFT MARKET: COMPANY SHARE 2016 (%)